Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.50 |
| ▸ | DAGLA | Q9Y4D2 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13426012 | 0.81 | NPC1 (0.46) | FAAHDAGLANPC1RAB9AKDM4E | |
| SCHEMBL3331863 | 0.81 | NPC1 (0.47) | FAAHDAGLANPC1RAB9AKDM4E | |
| SCHEMBL24921043 | 0.81 | FAAH (0.43) | FAAHDAGLANPC1RAB9AKDM4E | |
| SCHEMBL13662362 | 0.80 | FAAH (0.58) | FAAHDAGLACES1 | |
| SCHEMBL3967780 | 0.80 | FAAH (0.58) | FAAHDAGLACES1 | |
| SCHEMBL6632435 | 0.79 | FAAH (0.43) | FAAHDAGLANPC1RAB9AKDM4E | |
| SCHEMBL6920576 | 0.79 | NPC1 (0.44) | FAAHDAGLANPC1RAB9AKDM4E | |
| SCHEMBL1272691 | 0.78 | FAAH (0.45) | FAAHDAGLANPC1RAB9AKDM4E | |
| SCHEMBL11646668 | 0.77 | SMN1; SMN2 (0.53) | FAAHDAGLANPC1RAB9AKDM4E | |
| SCHEMBL17115152 | 0.77 | NPC1 (0.43) | FAAHDAGLANPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-07 | — | — | US | disclosed |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-02 | — | — | US | disclosed |
| US-20130017284-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUSIRT SCIENCES, INC. | 2013-01-17 | — | — | US | disclosed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| WO-2011032277-A1 | QUINAZOLINONE DERIVATIVES AS VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | WO | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-4131677-A | Anti-inflammatory oxazolo [5,4-b]pyridines | MERCK & CO., INC. (US) | 1978-12-26 | — | — | US | disclosed |
| US-4038396-A | ANTIPYRETICS, ANALGESICS | MERCK & CO., INC. (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | FAAH 970/4885DAGLA 4074/4885NPC1 896/4885 |
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | FAAH 970/4885DAGLA 4074/4885NPC1 896/4885 |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | FAAH 1756/4885DAGLA 3756/4885NPC1 3399/4885 |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | DHPS, HSD17B11, GNE | FAAH 1532/4885DAGLA 287/4885NPC1 618/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | FAAH 970/4885DAGLA 4074/4885NPC1 896/4885 |
| US-20130017284-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | PC, HADHB, ACACB | FAAH 2004/4885DAGLA 2416/4885NPC1 2090/4885 |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | FAAH 970/4885DAGLA 4074/4885NPC1 896/4885 |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | FAAH 802/4885DAGLA 3453/4885NPC1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.